Found 3 articles for: "Ruxolitinib"
Novel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreA Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo
July 2023 | Volume 22 | Issue 7 | Original Article | 664 | Copyright © July 2023
Background: This article describes the clinical trial, safety, and efficacy of ruxolitinib 1.5% cream or repigmentation in patients with vitiligo.Data Sources: A sys...
Read MoreSuccessful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy
March 2023 | Volume 22 | Issue 3 | Case Reports | 297 | Copyright © March 2023
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a ...
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.